The paradox of cancer genes in non-malignant conditions: implications for precision medicine
Abstract Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures. Intriguingly, rapidly emerging data indicate that altered genes representing oncogenic drivers can also be found i...
Main Authors: | Jacob J. Adashek, Shumei Kato, Scott M. Lippman, Razelle Kurzrock |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Genome Medicine |
Online Access: | http://link.springer.com/article/10.1186/s13073-020-0714-y |
Similar Items
-
179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
by: Razelle Kurzrock, et al.
Published: (2020-11-01) -
Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
by: Jacob J. Adashek, et al.
Published: (2020-08-01) -
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
by: Jacob J. Adashek, et al.
Published: (2021-07-01) -
Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
by: Nophar Geifman, et al.
Published: (2014-12-01) -
The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
by: Amélie Boichard, et al.
Published: (2020-01-01)